Axplora, a partner to Pharma companies and Biotechs for complex APIs, has appointed Martin Meeson as its new Chief Executive Officer (CEO).
 
Meeson succeeds Sylke Hassel. With over two decades of experience in managing and growing businesses globally, he brings a passion for this sector, the customers Axplora supplies and the partnerships it creates. Meeson will bring his expertise to Axplora’s global footprint of 10 sites on 3 continents while continuing to amplify the group’s capabilities and strengths in over 15 technologies including ADCs, Steroids & Industrial Chromatography. He is also committed to fostering growth and efficiency while building enduring partnerships with customers and other stakeholders.
 
Meeson, who took over as CEO of Fujifilm Diosynth Biotechnologies at the start of the pandemic, successfully steered the business through this turbulent period, supporting the development of numerous treatments and vaccines.
 
“What we do is not easy, but it is worthwhile.  In the pursuit of excellence, we must continue to build on our strengths and challenge ourselves to continuously improve for the partners and patients we serve,” Meeson remarked. “When deep technical expertise across the Axplora Group is positively matched with the needs of our over 900 customers, enduring success is realized for all players in the ecosystem.”